CEACAM1 and prostate carcinoma: Among the prostate cancer cell lines examined, PC3 and DU-145 expressed both the short and long cytoplasmic domain splice variants of CEACAM1: DU-145 cells expressed more of the short splice variant, PC3 cells largely expressed the long splice variant, and LNCaP cells expressed only the short splice variant (Fig. 3A cf. lanes 13–15).